Abstract 421P
Background
LEN is a multikinase inhibitor of VEGFRs 1–3, FGFRs 1–4, PDGFRα, RET, and KIT that resulted in significantly prolonged progression-free survival (PFS) compared with PBO in pts with RR-DTC in a phase III study (SELECT). However, SELECT did not include pts from China. As data in Chinese pts are required for approval of LEN for RR-DTC in China, we conducted a phase III study of RR-DTC treated with LEN vs PBO in Chinese pts.
Methods
This randomized, multicenter, double-blind, PBO-controlled study enrolled pts aged ≥18 years with RR-DTC and confirmed disease progression in the past 12 months. Pts were stratified by tumor subtype (papillary or follicular), number of prior VEGF/VEGFR-targeted therapies (0 or 1), and age (≤65 years or >65 years). LEN starting dose was 24 mg/day. The primary endpoint was PFS by independent imaging review based on RECIST v1.1. A one-sided significance level of 0.01 was utilized in the planned interim analysis. Secondary endpoints included overall response rate (ORR), overall survival, and safety.
Results
Overall, 151 Chinese pts (median age, 60 years; 52% men) were randomized 2:1 (LEN, n = 103; PBO, n = 48). At the recommendation of the Independent Data Monitoring Committee at the time of the interim analysis, the randomization phase of this study was stopped early because of positive efficacy and we conducted the primary analysis using the interim analysis cutoff date. In the LEN and PBO arms, the median durations of follow-up were 14.8 and 15.6 months, respectively. PFS was significantly improved with LEN (median 23.9 months; 95% CI 12.9–not estimable) vs PBO (median 3.7 months; 95% CI 1.9–5.6) (hazard ratio = 0.16, 95% CI 0.10–0.26; P < 0.0001 [logrank]). ORR was 69.9% with LEN and 0% with PBO. The most common treatment-related grade ≥3 adverse events (LEN, PBO) were hypertension (62.1%, 4.2%), proteinuria (23.3%, 0%), and palmar-plantar erythrodysesthesia syndrome (9.7%, 0%).
Conclusions
LEN significantly prolonged PFS compared with PBO in Chinese pts with RR-DTC, similar to the global phase III SELECT results. There were no new or unexpected toxicities with LEN in Chinese pts with RR-DTC.
Clinical trial identification
NCT02966093.
Editorial acknowledgement
Medical writing was provided by Oxford PharmaGenesis Inc., Newtown, PA, USA, and was funded by Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Eisai Co., Ltd., Tokyo, Japan, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA.
Funding
Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Disclosure
T. Kubota, T. Suzuki, H. Ikezawa: Full/Part-time employment: Eisai Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
153P - Mutational landscape of gastric cancer (GC) in adolescents and young adults (AYA) in Asia from 2015-2019
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
154P - A multicenter, prospective study of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer
Presenter: Yi-Hui Tang
Session: e-Poster Display Session
155P - Surgical outcomes and technical performance of robotic versus laparoscopic total gastrectomy for gastric cancer: A prospective comparative study FUGES-014
Presenter: Hua-Gen Wang
Session: e-Poster Display Session
156P - Safety and feasibility of laparoscopic spleen-preserving splenic hilar lymphadenectomy during total gastrectomy for advanced proximal gastric cancer: A randomized clinical trial
Presenter: Jian-Xian Lin
Session: e-Poster Display Session
157P - Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
Presenter: Amy Prawira
Session: e-Poster Display Session
158P - A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX study): Final report
Presenter: Atsuo Takashima
Session: e-Poster Display Session
159P - Open surgery can improve the 3-year postoperative survival in some patients with advanced gastric cancer compared with laparoscopic surgery: A multicenter, propensity score matching, in-depth analysis
Presenter: Ze-Ning Huang
Session: e-Poster Display Session
160P - Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Ning Li
Session: e-Poster Display Session
161P - Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis
Presenter: Chih Chieh Yen
Session: e-Poster Display Session
162P - Evaluation of neutrophil/lymphocyte ratio (NLR) in monitoring anastomotic leakage after radical total gastrectomy for gastric cancer
Presenter: Ru-Hong Tu
Session: e-Poster Display Session